Maria D. Montilla-Lopez

Cordoba, AN, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease.

Apremilast attenuates hepatic steatosis and metabolic dysfunction in a murine model of MASLD: Implications for patients with Psoriatic disease.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: September 27, 2025

Inflammatory protein profiling in immune cells identifies molecular signatures for enhanced diagnostic precision in psoriatic arthritis.

Inflammatory protein profiling in immune cells identifies molecular signatures for enhanced diagnostic precision in psoriatic arthritis.

Journal: Molecular biomedicine

Published: June 30, 2025

Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses.

Decoding clinical and molecular pathways of liver dysfunction in Psoriatic Arthritis: Impact of cumulative methotrexate doses.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 28, 2023

Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: Potential treatment targets.

Characterization of the inflammatory proteome of synovial fluid from patients with psoriatic arthritis: Potential treatment targets.

Journal: Frontiers in immunology

Published: December 29, 2022

Differences between early vs. late-onset of psoriatic arthritis: Data from the RESPONDIA and REGISPONSER registries.

Differences between early vs. late-onset of psoriatic arthritis: Data from the RESPONDIA and REGISPONSER registries.

Journal: Joint bone spine

Published: November 06, 2022

The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.

The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.

Journal: Journal of internal medicine

Published: March 02, 2022

Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis.

Complement component 3 as biomarker of disease activity and cardiometabolic risk factor in rheumatoid arthritis and spondyloarthritis.

Journal: Therapeutic advances in chronic disease

Published: May 14, 2020

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis.

Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis.

Journal: Therapeutic advances in musculoskeletal disease

Published: October 31, 2019

Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project.

Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project.

Journal: Reumatologia clinica

Published: October 20, 2017

Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients.

Circulating microRNAs as potential biomarkers of disease activity and structural damage in ankylosing spondylitis patients.

Journal: Human molecular genetics

Published: October 19, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026